Nanobiotechnology for health-care

Histological changes in internal organs under the action of C60-Cis-Pt nanocomplex

Lynchak O.V., Prylutska S.V., Kuznietsova G.M., Dziubenko N.V. 
Taras Shevchenko National University of Kyiv, 64/13, Volodymyrska str., 01601 Kyiv, Ukraine. 
E-mail: o.lynchak@gmail.com

Cisplatin (Cis-Pt) is one of the most widely used drugs for cancer treatment, however, its usage is limited by severe toxicity [1]. C60 fullerene is one of the most powerful antioxidants, which makes it an attractive substance as the basis for drug design. Complexation of Cis-Pt molecule with C60 fullerene one might allow to enhance the antitumor activity of the former and to reduce its adverse effects as well [2]. Therefore, possible toxic effects of the C60-Cis-Pt nanocomplex compared to free Cis-Pt were aimed to be discovered.   
The study was conducted on adult male mice. C60-Cis-Pt nanocomplex and free Cis-Pt were injected intraperitoneally at doses of 7,5, 15, 30, 45, 60, 75 and 90 mg/kg, control animals received saline instead. At the 15th day mice were sacrificed, autopsies of the main internal organs (liver, kidney, intestine, pancreas, spleen) were inspected visually and after histological processing on light microscopy slides. 
No significant anomalies were visually observed in the organs of all treated groups: size, sharp and color were unchanged, the organs weren’t enlarged. Histological examination of the organs of animals showed an aggravation of histopathological changes in a dose-dependent manner in both groups. The organs of mice received C60-Cis-Pt demonstrated the changes similar to those of ones received free Cis-Pt but much less expressed. Moreover, C60-Cis-Pt when applied in 15 and 30 mg/kg doses caused no significant morpho-functional changes in all examined organs unlike Cis-Pt.
Thus, C60-Cis-Pt nanocomplex caused the similar but much less expressed histopathological changes in main internal organs of mice compared to free Cis-Pt..

1.	Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action // Eur J Pharmacol. – 2014. – 740. – P. 364-378.
2.	Prylutska S., Politenkova S., Afanasieva K., Korolovych V., Bogutska K., Sivolob A., Skivka L., Evstigneev M., Kostjukov V., Prylutskyy Yu., Ritter U. A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity // Beilstein J Nanotechnol. – 2017. – 8. – P. 1494-1501.